Immuron Ltd — Regulatory Filings 2007

Mar 21, 2007

Company Announcement

Anadis to pursue Project Ectoplasm, for the containment and decontamination of hazardous materials

Thursday 22 March 2007

Anadis Limited (ASX:ANX) today announced that it is developing – in conjunction with Australian emergency response agencies, a major Australian Metropolitan Fire Brigade and the Defence Science and Technology Organisation – a system for the containment and decontamination of hazardous materials.

The system will use a gel-like substance, combined with an active agent such as Anadis' anti-anthrax antibodies, for use by emergency service first responders at the scene of an incident.

The gel will be sprayed on to the affected area, containing the damage. The antibodies will detect dangerous material and decontaminate the area. The gel is formed when the antibody preparation and the polymer concentrate – in either powder or liquid form – is fed into water spray via, for example, a backpack or fire-extinguisher-type unit.

Anadis has been working on the technology for more than a year and plans to have a first generation product on the market within 2 years. The company believes the product will generate significant international demand.

Anadis believes recent incidents worldwide have increased the need for such a technology. One such incident occurred in the United States in 2001, when letters containing anthrax bacteria were mailed to several news media offices and two US Senators, killing five people and causing illness among 17 others.

Anadis, a world leader in the production of specific antibodies with commerciallyproven production systems, has developed this program to utilise relatively low-cost, bulk specific antibodies in non-conventional applications.

This program has been named Project Ectoplasm as it relates to the delivery method of a technology through the use of a hydrogel medium.

Anadis believes the technology will provide a safer and significantly more effective method in dealing with hazardous materials resulting from, for example, an incident of deliberate contamination via a terrorism, or bio-terror event. These materials can include, but are not limited to, bacteria (anthrax and plague), viruses and toxins (botulinum and ricin toxins).

Key advantages of this program are:

• Flexible system for dealing with large scope of contaminant emergency response situations.
• Federal Government and Response Agency support.
• Large global market among emergency response agencies.
• Highly reduced risk for emergency response personnel.
• Safer methods of containment.
• Decreased risk in contamination spread (eg through air ducts)
• Patent protected technology.

For further information, please contact:

Dr Grant Rawlin - Head of R&D

Email: grant.r@anadis.com.au Tel: +61 3 9358 6388

Arie Nudel – Investor Relations

Email: arie.n@anadis.com.au Tel: $+61$ 3 9358 6388

Richard Allen - Media

Email: richard@oxygenpr.com.au, Tel: +61 3 9915 6341

About Anadis Limited:

Anadis, a Melbourne-based biopharmaceutical company, is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of dairy (bovine) colostrum-derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decreases the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a colostrum preparation, against the common strains of E, coli – the most common cause of Travellers Diarrhoea.

Travelan, which has been approved for distribution in North America, now has US and Canadian distributors appointed. Travelan distribution is currently being developed for other markets including: Singapore, India, Korea, United Arab Emirates, Thailand, Malaysia, South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome and Inflammatory Bowel Disorder.

For more information please visit www.travelan.com

$EV-71$ – a bioactive protein based preventative product against Enterovirus 71, a debilitating polio-like disease – is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of younger children effected can develop nervous signs such as fits and paralysis. Enterovirus 71 can be fatal. Anadis is preparing colostrum antibodies for commercialisation in an anti-EV71 preventative, set to begin marketing in Taiwan during the northern hemisphere summer of 2007.

A set of Bio-Defence and Respiratory Protection technologies – a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations - initially focused on short-term immediate protection from airborne bacteria such as anthrax and plague. Future civilian applications include hay fever and asthma.

This project is expanding to examine the use of antibodies in providing respiratory protection against Influenza virus.

Bio-Shield 10 a range of bio-shielding technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H. pylori bacteria in the stomach and reduce the symptoms of H, pylori associated gastritis. Anadis is also in early development of an $H$ . pylori vaccine.

Anadis - Delivering on the Promise of Biotechnology

Visit our websites: www.anadis.com.au and www.travelan.com